Weight loss : up to 15-21% of total body weight over the 72-week treatment period, with many individuals losing upwards of 50 pounds, according to the landmark SURMOUNT-1 clinical trial published in 2022
In mid-2024, the Endocrine Society warned that online prescribing of compounded GLP-1s poses patient safety risks and undermines public confidence in obesity care. The organization called for stricter verification of clinicians and for oversight of digital compounding networks that have limited traceability or pharmacovigilance. Their concern echoed that of the FDA , which, after investigating multiple adverse-event reports linked to unapproved semaglutide, issued formal warnings to both compounders and telehealth distributors
Keywords: Pregnant Women, Safety, Diabetes in pregnancy, Obesity STRENGTHS AND LIMITATIONS OF THIS STUDY
Zhou, Y., Wang, S., Li, Y., Yu, S
It usually resolves within the first month at each dose level
For more information, visit www.lifevantage.com .* *These statements have not been evaluated by the Food and Drug Administration